Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Acute Lymphoblastic Leukemia
68%
BCP-ALL
59%
Minimal Residual Disease
42%
Pediatric
40%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
31%
IKZF1
22%
Childhood Acute Lymphoblastic Leukemia
19%
Event-free Survival
19%
Hyperdiploid
18%
ETV6-RUNX1
17%
Relapsed or Refractory
15%
Pediatric Patients
15%
Leukemia
15%
Leukemia Patients
15%
RNA Sequencing (RNA-seq)
15%
Paediatric B-cell Precursor Acute Lymphoblastic Leukaemia
15%
Pediatric Acute Lymphoblastic Leukemia
14%
IKZF1 Deletion
13%
Tyrosine Kinase Inhibitor
13%
Overall Survival
13%
Copy number Variation
12%
Acute Lymphoblastic Leukemia Cells
11%
Children with Cancer
11%
Intrachromosomal Amplification of Chromosome 21 (iAMP21)
11%
Gemtuzumab Ozogamicin
11%
Personalized Therapy
11%
Cancer Program
11%
Precision Oncology
11%
Clinical Practice
11%
Confidence Interval
11%
Targeted Therapy
11%
High Risk
11%
PAX5
10%
Aberrations
10%
Hematopoietic Stem Cell Transplantation
10%
Media Risk
9%
Leukemic Cells
9%
Dutch
9%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
9%
Poor Outcome
9%
CD22
8%
BCR-ABL1
8%
Clinical Trials
7%
Signal Transduction Inhibitors
7%
Bone Marrow
7%
Copy number
7%
Therapeutic Target
7%
Pediatric Cancer
7%
Improved Outcomes
7%
Risk Stratification
7%
Whole Exome Sequencing
7%
Clinical Outcomes
6%
B-cell Precursors
6%
Standard Risk
6%
Overall Response Rate
6%
Primary B Cells
6%
Mesenchymal Stromal Cells
6%
Blood Cancer
6%
Drug Resistance
6%
Fusion Gene
6%
Risk Score
6%
TCF3-PBX1
6%
Genetic Subtypes
6%
Lymphoblastic Malignancies
6%
Extramedullary
6%
B Cell Development
6%
DUX4
6%
Cell Tumor
6%
Chromosomal Instability
6%
Hyperdiploidy
6%
Janus Kinase 2 (JAK2)
6%
Relapse Risk
6%
Precision Medicine
6%
Germ Cells
5%
Phase II Trial
5%
Tyrosine Kinase Inhibitor Resistance
5%
Kinase Domain mutations
5%
Antibody-dependent Cellular Phagocytosis
5%
Prognostic Effect
5%
Central Nervous System Involvement
5%
AUTS2
5%
Childhood B-ALL
5%
Transcriptional Landscape
5%
Mutational Landscape
5%
Lymphoblastic Lymphoma
5%
Ara-C
5%
Common Region
5%
IKZF1 Gene Deletion
5%
Cytarabine
5%
Oncogenic Targets
5%
Genomic Deletion
5%
Ibrutinib
5%
Precursor B-cell
5%
RNA-DNA
5%
Interferon-β (IFN-β)
5%
Secondary Lesions
5%
Gene Deletion
5%
Interleukin-7 Receptor
5%
Tumor Suppression
5%
Tumor
5%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Pediatrics
50%
B Cell
46%
Precursor
37%
Minimal Residual Disease
37%
Acute B-Cell Lymphoblastic Leukemia
22%
Malignant Neoplasm
18%
Pediatrics Patient
15%
Personalized Medicine
15%
Neoplasm
14%
Leukemia in Children
12%
Overall Survival
12%
Inotuzumab Ozogamicin
11%
Leukemia
11%
Risk Stratification
10%
Germ Cell
10%
Hematopoietic Stem Cell Transplantation
9%
Leukemia Cell
9%
Event Free Survival
9%
RNA Sequence
8%
Adolescence
7%
High Risk Population
7%
Clinical Trial
7%
Hematological Cancer
7%
Cancer
6%
Prognostic Factor
6%
Janus Kinase
6%
Targeted Therapy
6%
Pediatric Cancer
6%
Tyrosine-Kinase Inhibitor
5%
Oncology
5%
Medicine
5%
Retrospective Cohort Study
5%
Protein P53
5%
Infectious Complication
5%
Down Syndrome
5%
Ibrutinib
5%
Stroma
5%
Interferon
5%
Calicheamicin
5%
Chromosome 21
5%
Phase II Trials
5%
microRNA
5%
Carcinogenesis
5%
Cohort Analysis
5%
Cyclin C
5%
Precision Oncology
5%
Long-Term Outcome
5%
Chronic Myelogenous Leukemia
5%
Mesenchymal Stem Cell
5%
Biochemistry, Genetics and Molecular Biology
B Cell
98%
Precursor
80%
IKZF1
25%
RNA Sequence
21%
Chromosome 21
18%
ETV6
18%
RUNX1
18%
High Risk Population
15%
Overall Survival
12%
Germline
11%
Germ Cell
11%
Tyrosine Kinase Inhibitor
11%
Kinase
11%
Phosphotransferase
11%
Genetics
11%
Down Syndrome
11%
Event Free Survival
11%
Clinical Trial
10%
PAX5
9%
Cytogenetics
7%
T Cell
7%
Targeted Therapy
7%
Exome Sequencing
6%
Enhancer Region
6%
DUX4
6%
Chromosome Instability
6%
Drug Resistance
6%
Janus Kinase
6%
Cell Viability
6%
Cell Maturation
6%
SH3 Domain
5%
Gene Deletion
5%
Cytarabine
5%
Stem Cell
5%
Spindle Checkpoint
5%
Interferon
5%
MicroRNA
5%
Philadelphia Chromosome
5%
Aurora B Kinase
5%
Condensin
5%
Cryopreservation
5%
DNA Methylation
5%
Cell Function
5%
DNA RNA Hybridization
5%
CD22
5%
Autophagy
5%
Blood Plasma
5%
B-Cell Receptor
5%
KMT2A
5%
BCL11B
5%
CDKN2B
5%
Coculture
5%
Tyrosine Kinase
5%
Receptor Tyrosine Kinase
5%
Single-Nucleotide Polymorphism
5%
Fluorescence in Situ Hybridization
5%